Abstract
A 33-year-old woman with T(4c)N(3) breast cancer with metastases in the skeleton (M(1)) received five cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC regimen) before conception and during the first trimester. Salvage radiotherapy (28 Gy) was delivered during the 17th week. Tamoxifen and zolendronic acid were also administered throughout the second and third trimesters. The patient was not aware of her pregnancy until the 28th week. A female phenotypically normal infant was delivered in the 35th week of gestation by cesarean section. The child is functioning normally 12 months after delivery. The literature of anthracycline treatment during conception and the first trimester is reviewed. The effects of tamoxifen and biphosphonate therapy on the fetus during pregnancy are also discussed.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Neoplasms / secondary
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Breast Neoplasms / radiotherapy*
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Diphosphonates / administration & dosage
-
Epirubicin / administration & dosage
-
Epirubicin / adverse effects
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Humans
-
Imidazoles / administration & dosage
-
Pregnancy
-
Pregnancy Complications, Neoplastic / drug therapy*
-
Pregnancy Complications, Neoplastic / pathology
-
Pregnancy Complications, Neoplastic / radiotherapy*
-
Pregnancy Outcome
-
Salvage Therapy
-
Tamoxifen / administration & dosage
-
Tamoxifen / adverse effects
-
Zoledronic Acid
Substances
-
Diphosphonates
-
Imidazoles
-
Tamoxifen
-
Epirubicin
-
Zoledronic Acid
-
Cyclophosphamide
-
Fluorouracil